# Mira Pharmaceuticals, Inc.: financial statements, quarterly

MIRA · Nasdaq · CIK 1904286 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/mira.md) · [Financials](/companies/mira/financials.md) · [Filings](/companies/mira/filings.md) · [Insiders](/companies/mira/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mira/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [1,015](/filings/0001493152-24-044747.md) | [387 d](/filings/0001641172-25-001183.md) | [762](/filings/0001641172-25-010301.md) | [614](/filings/0001641172-25-024077.md) | [1,067](/filings/0001493152-25-022112.md) | [861 d](/filings/0001493152-26-014001.md) | [314](/filings/0001493152-26-023005.md) | [496](/filings/0001493152-26-037366.md) | [413](/filings/0001493152-25-022112.md) | [497 d](/filings/0001493152-26-014001.md) | [525](/filings/0001493152-26-023005.md) | [706](/filings/0001493152-26-037366.md) |
| Interest expense | $k | [428](/filings/0001493152-24-044747.md) | [2,731 d](/filings/0001641172-25-001183.md) | [(50.4)](/filings/0001641172-25-010301.md) | [(39.4)](/filings/0001493152-24-032816.md) | [(37.8)](/filings/0001493152-24-044747.md) | [(38.1) d](/filings/0001641172-25-001183.md) | [(21.4)](/filings/0001641172-25-010301.md) | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,588)](/filings/0001493152-24-044747.md) | [(5,787) d](/filings/0001641172-25-001183.md) | [(1,718)](/filings/0001493152-25-022112.md) | [(1,691)](/filings/0001493152-25-022112.md) | [(2,044)](/filings/0001493152-25-022112.md) | [(2,400) d](/filings/0001493152-26-014001.md) | [(1,784)](/filings/0001493152-26-037366.md) | [(1,538)](/filings/0001493152-26-037366.md) | [(1,138)](/filings/0001493152-25-022112.md) | [(5,983) d](/filings/0001493152-26-014001.md) | [(1,150)](/filings/0001493152-26-037366.md) | [(1,209)](/filings/0001493152-26-037366.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001493152-24-044747.md) | not reported | [(0.15)](/filings/0001641172-25-010301.md) | [(0.11)](/filings/0001641172-25-024077.md) | [(0.14)](/filings/0001493152-25-022112.md) | not reported | [(0.11)](/filings/0001493152-26-023005.md) | [(0.09)](/filings/0001493152-26-037366.md) | [(1.18)](/filings/0001493152-25-022112.md) | not reported | [(0.03)](/filings/0001493152-26-023005.md) | [(0.03)](/filings/0001493152-26-037366.md) |
| Basic EPS | $ per share | [(0.26)](/filings/0001493152-24-044747.md) | not reported | [(0.15)](/filings/0001641172-25-010301.md) | [(0.11)](/filings/0001641172-25-024077.md) | [(0.14)](/filings/0001493152-25-022112.md) | not reported | [(0.11)](/filings/0001493152-26-023005.md) | [(0.09)](/filings/0001493152-26-037366.md) | [(1.18)](/filings/0001493152-25-022112.md) | not reported | [(0.03)](/filings/0001493152-26-023005.md) | [(0.03)](/filings/0001493152-26-037366.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | period not labelled (2025-07-18) | Q3 FY2025 (2025-09-30) | period not labelled (2025-12-16) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.5](/filings/0001493152-24-018908.md) | [2.8](/filings/0001493152-24-032816.md) | [4.1](/filings/0001493152-24-044747.md) | [2.8](/filings/0001493152-26-014001.md) | [1.2](/filings/0001641172-25-010301.md) | [0.7](/filings/0001641172-25-024077.md) | [0.1](/filings/0001493152-26-014001.md) | [2.6](/filings/0001493152-25-022112.md) | [0.1](/filings/0001493152-26-014001.md) | [6.3](/filings/0001493152-26-037366.md) | [0.1](/filings/0001493152-26-037366.md) | [3.6](/filings/0001493152-26-037366.md) |
| Current assets | $m | [3.7](/filings/0001493152-24-018908.md) | [2.9](/filings/0001493152-24-032816.md) | [4.2](/filings/0001493152-24-044747.md) | [2.9](/filings/0001493152-26-014001.md) | [1.4](/filings/0001641172-25-010301.md) | [0.8](/filings/0001641172-25-024077.md) | not reported | [7.6](/filings/0001493152-25-022112.md) | not reported | [11.1](/filings/0001493152-26-037366.md) | [9.4](/filings/0001493152-26-023005.md) | [8.2](/filings/0001493152-26-037366.md) |
| Total assets | $m | [3.8](/filings/0001493152-24-018908.md) | [3.0](/filings/0001493152-24-032816.md) | [4.3](/filings/0001493152-24-044747.md) | [2.9](/filings/0001493152-26-014001.md) | [1.4](/filings/0001641172-25-010301.md) | [0.9](/filings/0001641172-25-024077.md) | not reported | [7.6](/filings/0001493152-25-022112.md) | not reported | [11.1](/filings/0001493152-26-037366.md) | [9.5](/filings/0001493152-26-023005.md) | [8.2](/filings/0001493152-26-037366.md) |
| Current liabilities | $m | [0.7](/filings/0001493152-24-018908.md) | [0.8](/filings/0001493152-24-032816.md) | [0.7](/filings/0001493152-24-044747.md) | [0.7](/filings/0001493152-26-014001.md) | [0.1](/filings/0001641172-25-010301.md) | [0.3](/filings/0001641172-25-024077.md) | not reported | [0.1](/filings/0001493152-25-022112.md) | not reported | [0.7](/filings/0001493152-26-037366.md) | [0.1](/filings/0001493152-26-023005.md) | [0.0](/filings/0001493152-26-037366.md) |
| Total liabilities | $m | [0.7](/filings/0001493152-24-018908.md) | [0.8](/filings/0001493152-24-032816.md) | [0.7](/filings/0001493152-24-044747.md) | [0.7](/filings/0001493152-26-014001.md) | [0.1](/filings/0001641172-25-010301.md) | [0.3](/filings/0001641172-25-024077.md) | not reported | [0.1](/filings/0001493152-25-022112.md) | not reported | [0.7](/filings/0001493152-26-037366.md) | [0.1](/filings/0001493152-26-023005.md) | [0.0](/filings/0001493152-26-037366.md) |
| Shareholders' equity | $m | [3.2](/filings/0001493152-25-022112.md) | [2.2](/filings/0001493152-25-022112.md) | [3.6](/filings/0001493152-25-022112.md) | [2.2](/filings/0001493152-26-037366.md) | [1.3](/filings/0001493152-26-037366.md) | [0.6](/filings/0001493152-26-037366.md) | not reported | [7.5](/filings/0001493152-25-022112.md) | not reported | [10.4](/filings/0001493152-26-037366.md) | [9.3](/filings/0001493152-26-037366.md) | [8.2](/filings/0001493152-26-037366.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,761) d](/filings/0001493152-24-044747.md) | [(1,035) d](/filings/0001641172-25-001183.md) | [(1,050)](/filings/0001641172-25-010301.md) | [(864) d](/filings/0001641172-25-024077.md) | [(1,842) d](/filings/0001493152-25-022112.md) | [(1,805) d](/filings/0001493152-26-014001.md) | [(1,630)](/filings/0001493152-26-023005.md) | [(800) d](/filings/0001493152-26-037366.md) | [(1,097) d](/filings/0001493152-25-022112.md) | [(1,135) d](/filings/0001493152-26-014001.md) | [(1,201)](/filings/0001493152-26-023005.md) | [(1,206) d](/filings/0001493152-26-037366.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2022-06-30) | period not labelled (2022-09-30) | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.1](/filings/0001493152-23-032778.md) | [13.2](/filings/0001493152-23-040517.md) | [17.8](/filings/0001493152-24-018908.md) | [13.3](/filings/0001493152-24-032816.md) | [13.6](/filings/0001493152-24-044747.md) | [14.8](/filings/0001641172-25-010301.md) | [14.8](/filings/0001641172-25-024077.md) | [15.1](/filings/0001493152-25-022112.md) | [16.6](/filings/0001641172-25-010301.md) | [17.0](/filings/0001641172-25-024077.md) | [19.3](/filings/0001493152-25-022112.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,022,087 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001493152-26-037366.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.